Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic
haemolytic anaemia and end organ damage. TMAs have varying underlying …

The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date
and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) …

Background The collagen receptor glycoprotein VI (GPVI) is an attractive antiplatelet target
due to its critical role in thrombosis but minor involvement in hemostasis. Objective To …

Abstract Background The von Willebrand factor–directed nanobody caplacizumab has
greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in …

Immune thrombotic thrombocytopenic purpura (iTTP) is an acquired, fatal microangiopathy if
untreated. Randomized controlled trials (RCTs) demonstrated faster time to response with …

Background Endotheliopathy and coagulopathy appear to be the main causes for critical
illness and death in patients with coronavirus disease 2019 (COVID-19). The adhesive …

Introduction Caplacizumab demonstrated efficacy and safety in patients with immune‐
mediated thrombotic thrombocytopenic purpura (iTTP) in the phase 3 HERCULES trial …

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare hematologic
disease caused by autoantibodies against ADAMTS-13 that trigger microangiopathic …

Thrombotic thrombocytopenic purpura (TTP) is a fatal disease in which platelet-rich
microthrombi cause end-organ ischemia and damage. TTP is caused by markedly reduced …